Search for: "Amgen Inc. v. Harris"
Results 21 - 38
of 38
Sorted by Relevance
|
Sort by Date
25 Jan 2016, 1:31 pm
In the second summary ruling, in Amgen Inc., v. [read post]
19 May 2023, 4:03 pm
The justices ruled in favor of social media companies in Twitter, Inc. v. [read post]
29 Jul 2010, 6:48 pm
" Amgen Inc. v. [read post]
19 Dec 2013, 6:12 am
Amgen, Inc., ___ F.3d. ___, 2013 WL 5737307, at *6 (9th Cir. [read post]
12 Jun 2017, 12:15 pm
Amgen Inc., regarding the Biologics Price Competition and Innovation Act of 2009. [read post]
18 Jan 2017, 6:40 am
– Amgen, Inc. v. [read post]
19 Feb 2011, 3:32 pm
§ 282, or the "rebuttable presumption that different claims are of different scope," Amgen Inc. v. [read post]
8 Nov 2007, 11:56 pm
ALM Privacy Policy / Contact Us
© 2007 ALM Properties, Inc. [read post]
2 Jan 2019, 10:26 am
” Here plaintiff Jander argued that no duty-of-prudence claim against an ESOP fiduciary has passed the motion-to-dismiss stage since the 2010 decision in Harris v. [read post]
22 Feb 2008, 1:30 pm
The decision in Reidel v. [read post]
28 Mar 2008, 6:00 am
: (Afro-IP),If education and pricing policy fail, says Adobe in Nigeria, we can still sue: (Afro-IP),South African arm of Chrysler objects to advertisement by Indian vehicle maker Mahindra and Mahindra that uses the term "jeep": (Afro-IP), (Spicy IP),Kenya’s call for anti-counterfeit legislation… amongst other changes: (Afro-IP),Kenya: Shared computer use raises privacy, confidentiality issues: (Afro-IP)AustraliaChanges to grace period for trade mark renewal:… [read post]
18 Apr 2008, 2:00 am
Lélos Kai Sia EE (and Others) v GlaxoSmithKline AEVE: (IPKat), US: Bio commends Sen Specter for patent reform stance: (Patent Docs), US: USPTO rules on two of four neural stem cell patents in dispute between StemCells Inc and Neuralstem Inc; parties disagree on how extensively claims amended: (IP Law360), (IPBiz), US: Insmed continues fight for generic biologic approval: (GenericsWeb), Pharma & Biotech - Products Cipralex (Escitalopram)… [read post]
12 Sep 2008, 2:33 pm
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Australian Review of National Innovation System released: (IPRoo), (Mallesons Stephen Jaques), (creativecommons.org), (IP Menu News), Senate Committee on the Judiciary approval of Enforcement of Intellectual Property Rights Act 2008 and surrounding debate (Law360), (Public Knowledge), (Ars Technica), (Wired), (Public Knowledge), (Ars Technica),… [read post]
2 May 2008, 7:00 am
: (Patent Baristas), US: How to avoid a permanent injunction: the lessons of Amgen v Hoffman-LaRoche: (Patent Docs), US: Jarvik Heart’s PTE request based on PMA shell/module submission dates flatlines; ruling on initiation of PTE ‘review period’ mirrors FDA policy for ‘fast track’ products: (FDA Law Blog) Pharma & Biotech - Products Kytril (Granisetron) – Exclusivity ‘parking’… [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in India and… [read post]
11 Feb 2008, 8:08 am
Amgen, Inc., No. 07-1999 "In an action against defendant charging fraudulent pricing of pharmaceutical drugs in violation of Wisconsin state law, an order remanding the case and sanctioning defendant is affirmed in part as to the remand order, but reversed as to the sanctions where: 1) the filing of a suit under the False Claims Act did not render this case removable; and 2) the paucity of appellate authority on the removability issue gave defendant a reasonable basis for… [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007: (Patent… [read post]
